32results about How to "Avoid systemic side effects" patented technology

A low-concentration atropine as eye medicine for treating myopia, cataract, retinosis, etc is disclosed. Its advantages are not afraid of light and high suppleness.

Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions.

Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions.

Herein is reported a polypeptide comprising a first polypeptide and a second polypeptide each comprising in N-terminal to C-terminal direction at least a portion of an immunoglobulin hinge region, which comprises one or more cysteine residues, an immunoglobulin CH2-domain and an immunoglobulin CH3-domain, wherein

• • i) the first and the second polypeptide comprise the mutations H310A, H433A and Y436A, or
  • ii) the first and the second polypeptide comprise the mutations L251D, L314D and L432D, or
  • iii) the first and the second polypeptide comprise the mutations L251S, L314S and L432S.

The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given in the specification, or a pharmacologically-acceptable salt or ester thereof. The disease or conditions treatable according to the invention include angiogenic diseases and conditions of the eye, angiogenic diseases and conditions of the brain, inflammatory diseases and conditions of the eye, inflammatory diseases and conditions of the brain and neurodegenerative diseases.

The present invention generally relates to transdermal drug delivery systems. More particularly, the present invention provides compositions and transdermal drug delivery systems for the treatment and/or relief of symptoms associated with carpal tunnel syndrome or tendonitis.

A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.

The invention discloses a fluticasone propionate foaming agent composition, which contains fluticasone propionate serving as an active ingredient and one or more pharmaceutically acceptable auxiliary materials for a foaming agent, wherein the content of the fluticasone propionate serving as the active ingredient is 0.05 to 0.2 percent (weight/weight), and the volume expansion ratio of the foaming agent composition is 25 to 50.

A pharmaceutically acceptable deliverable composition and methods for administration of macromolecules for sequence-specific gene-silencing in bladder to treat overactive bladder (OAB), interstitial cystitis/painful bladder syndrome (IC/PBS), lower urinary tract symptoms (LUTS) locally in the bladder, or other diseases or disorders of the bladder or LUTS, has been discovered. In the preferred embodiment, a liposome based delivery system is used to deliver an effective amount of antisense oligonucleotides (ODN) or siRNA that interact with or bind to messenger RNA (mRNA) coding for human nerve growth factor (NGF) to stop the synthesis of NGF.

The invention relates to an anti-microbe drug which uses poly acid anhydride as carrier. The invention uses poly acid anhydride (as fatty group poly acid anhydride, aromatic nucleus poly acid anhydride, phosphor poly acid anhydride, polyamide poly acid anhydride, polyester poly acid anhydride or the like or their polymer) as carrier to be mixed via the drug, to be heated and fused into biological degradable slow-release agent. The inventive agent can be prepared into disc and rod shapes via mould according to the clinic demands. And the external degradation test has proved that the drug can reach zero-level release, without instant-release effect, to realize the slow-release object and confirm the safety.

The present invention relates to a fusion protein comprising therapeutical and diagnostic potential against chronic vascular diseases, such as atherosclerosis, a nucleic acid molecule encoding said fusion protein, a pharmaceutical and diagnostic composition which comprises the fusion protein or the nucleic acid molecule, the use of the fusion protein or the nucleic acid molecule for the production of a pharmaceutical and diagnostic composition, a method for the diagnosis of acute or chronic vascular diseases, and a method for the production of a fusion protein.

The invention provides tofacitinib nanocrystal eye drops for treating immunity-related eye diseases and a preparation method thereof, and the tofacitinib nanocrystal eye drops are prepared by the following steps: dispersing micronized tofacitinib in a surfactant solution at a high speed, then mixing with a stabilizer, uniformly dispersing, and then carrying out high-pressure homogenization circulation, so as to obtain the tofacitinib nanocrystal eye drops. The tofacitinib nanocrystal eye drops meeting the particle size requirement are obtained. Wherein the surfactant is P188-lecithin, and the stabilizer is any one or a mixture of more of HPMC (Hydroxy Propyl Methyl Cellulose), polyvinyl alcohol and HPMC-docusate sodium. Through cooperation of the surfactant and the stabilizer, the particle size and the potential of the eye drops are influenced, the stability and the adhesiveness are improved, the residence time of the medicine in eyes is prolonged, and the medicine carrying rate is high. The loss speed of the medicine in front of the cornea is reduced, so that the medicine can be slowly released, the eye drop frequency of a patient is reduced, the compliance of the patient is improved, and a good clinical application prospect is achieved.

A method of pharmaceutical therapy comprising the co-administration of any form of interferon or any derivative thereof with a low dose of ribavirin (less than 400 mg /day or less than 6 mg/kg/day), or related compound, where the ribavirin or related compound provides a clinically effective blood level in the portal circulation but a less than clinically effective blood level in the peripheral circulation, to thereby provide a systemic effect of interferon throughout the body but a selective effect of ribavirin in the liver. The method also provides for the co-administration of any form of interferon or any derivative thereof with a high dose of ribavirin (preferably from 400-800 mg/day), or related compound, where the ribavirin or related compound is administered as a slow-release formulation such that it also provides a sustained virologic response in a patient and reduced side effects. The method also provides for the co-administration of an antioxidant or other membrane protective agent with both the interferon and ribavirin such that the hepatoprotective activity of the antioxidant or other membrane protective agent complements the virucidal effect of the interferon and ribavirin. The antioxidant or other membrane protective agent may be administered as a systemic or a low-dose, slow-release, liver-selective formulation.